The nature-derived AI biotech hit a $2 billion valuation as it pushes candidates for skin conditions and post-GLP-1 weight maintenance into clinical trials.
Enveda closed a $311 million round that values the company at $2 billion, capital it will use to advance AI-discovered, nature-derived drug candidates through clinical trials. The pipeline includes treatments for skin conditions and a compound designed to preserve weight loss after patients stop taking GLP-1 drugs.
The raise lands as investors keep betting on AI-native biotechs that can show a credible path from model output to human trials, not just research papers.
A $2B valuation signals investors still reward AI drug discovery shops that can point to trial-stage assets, not just algorithms. For biotech leadership, Enveda's GLP-1 follow-on play shows where the next commercial wedge in weight-loss drugs is forming.
The daily signal, curated. Get it in your inbox.
Subscribe on LinkedIn →